Complement C1s subcomponent — Drug Target

All drugs that target Complement C1s subcomponent — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Classical Complement Pathway Inhibitor [EPC]

Marketed (2)

• Enjaymo · Bioverativ Therapeutics Inc · Classical Complement Pathway Inhibitor [EPC] · Immunology
  Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells.
• ENJAYMO · RECORDATI RARE DISEASES, INC. · Classical Complement Pathway Inhibitor [EPC] · Immunology